Applied BioCode Corporation (TWSE: 6598)
Health Care · Health Care Equipment & Supplies · KY
NT$28.55
+2.70% today · +45.7% 1Y
Applied BioCode Corporation (TWSE: 6598) operates in the Health Care Equipment & Supplies industry within the Health Care sector. The company is valued at $92.19M and employs 43 people.
Over the last twelve months the share price has gained 45.7%, trading between 19.25 and 31.90.
Tweenvest scores Applied BioCode Corporation across four factors: quality 48/100, value 74/100, growth 86/100. Its strongest factor is growth.
6598 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $92.19M
- Revenue (TTM)
- $17.90M
- P/E
- —
- EPS
- -1.41
- Dividend yield
- —
- Beta (5Y)
- 0.65
- 52-week high
- NT$31.90
- 52-week low
- NT$19.25
- Avg volume (3M)
- —
- Shares outstanding
- 102.82M
- Employees
- 43
- Next earnings
- —
About Applied BioCode Corporation
Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.
- ISIN
- KYG0488D1051
- Founded
- 2016
- Listed since
- Feb 9, 2017
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Health Care Equipment & Supplies companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Abbott LaboratoriesNYSE: ABT | $200.95B | $114.76 | -1.18% |
| Intuitive Surgical, Inc.NasdaqGS: ISRG | $131.36B | $369.60 | -0.60% |
| Stryker CorporationNYSE: SYK | $126.81B | $331.52 | +0.28% |
| Medtronic plcNYSE: MDT | $116.66B | $92.29 | +1.26% |
| EssilorLuxottica Société anonymeENXTPA: EL | $85.36B | €159.20 | +0.03% |
| Boston Scientific CorporationNYSE: BSX | $72.26B | $48.06 | -3.62% |
| HOYA CorporationTSE: 7741 | $52.49B | ¥24,995.00 | +0.40% |
| Edwards Lifesciences CorporationNYSE: EW | $52.38B | $91.11 | +0.26% |
Figures last refreshed Aug 18, 2026.